Grail (GRAL) to Release Earnings on Tuesday

Grail (NASDAQ:GRAL) will likely be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 13th. Analysts expect Grail to post earnings of ($4.03) per share and revenue of $35.80 million for the quarter.

Grail (NASDAQ:GRAL) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $35.33 million. On average, analysts expect Grail to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Grail Stock Performance

Shares of GRAL stock opened at $35.20 on Monday. The company’s fifty day moving average price is $29.54 and its 200-day moving average price is $25.87. Grail has a 12 month low of $12.33 and a 12 month high of $63.99.

Insider Transactions at Grail

In other news, President Joshua J. Ofman sold 2,109 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $65,800.80. Following the sale, the president now owns 559,673 shares in the company, valued at $17,461,797.60. This represents a 0.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Aaron Freidin sold 41,150 shares of the firm’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $33.93, for a total transaction of $1,396,219.50. Following the sale, the chief financial officer now directly owns 294,020 shares of the company’s stock, valued at $9,976,098.60. This trade represents a 12.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 194,948 shares of company stock valued at $6,583,130 in the last quarter. 1.85% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GRAL has been the topic of several research reports. Morgan Stanley boosted their price objective on shares of Grail from $16.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 18th. Canaccord Genuity Group assumed coverage on Grail in a research report on Monday, April 21st. They issued a “buy” rating and a $32.00 price target on the stock.

About Grail

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.